Cargando…

Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (Trop-2) and precision treatment of breast cancer

Detalles Bibliográficos
Autores principales:	Stenvang, Jan, Vestlev, Peter Michael, Jensen, Benny Vittrup, Pfeiffer, Per
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708494/ https://www.ncbi.nlm.nih.gov/pubmed/36467370 http://dx.doi.org/10.21037/atm-22-4581

Ejemplares similares

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer
por: Matusz-Fisher, Ashley, et al.
Publicado: (2022)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
por: Goldenberg, David M., et al.
Publicado: (2018)

Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
por: Jeon, Yeonjin, et al.
Publicado: (2022)

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015)

AB007. Expression of trophoblastic antigen 2 (Trop2) in thymic epithelial tumors
por: Yeung, Vincent, et al.
Publicado: (2022)

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
por: Hoppe, Sascha, et al.
Publicado: (2022)

Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target
por: Wolber, Philipp, et al.
Publicado: (2021)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Site-Specific Antibody Conjugation for ADC and Beyond
por: Zhou, Qun
Publicado: (2017)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022)

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
por: Santi, Daniel V., et al.
Publicado: (2021)

Nano - drug Delivery of Apoptosis Activator 2 to AGS Cells by Liposomes Conjugated with Anti-TROP2 Antibody
por: Farivar, Taghi Naserpour, et al.
Publicado: (2012)

Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
por: Yao, Houzong, et al.
Publicado: (2016)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer – The ABCs of ADCs (Antibody drug Conjugates)()
por: Martin, J., et al.
Publicado: (2023)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)

From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
por: Mantaj, Julia, et al.
Publicado: (2016)

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies
por: Kang, Xiuhua, et al.
Publicado: (2018)

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
por: Mahmood, Iftekhar
Publicado: (2021)

Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
por: Mahmood, Iftekhar
Publicado: (2021)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer
por: Mao, Yuan, et al.
Publicado: (2016)

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
por: Xu, Caili, et al.
Publicado: (2023)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
por: Lambert, John M., et al.
Publicado: (2017)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs
por: Kumar, Amit, et al.
Publicado: (2018)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
por: Hammood, Manar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a51r61ot06hbcb23hal6594ppd